ETR has the potential for drug-drug interaction (DDI) with CYP2C8, CYP2C9, and CYP3A4 when coadministered with inhibitors or inducers of these enzymes. This open-label Phase 1 study evaluated the ...

Several clinical trials have demonstrated the relative tolerability of losartan. [8,14,18,19,20] The most frequent adverse reaction, as observed in a clinical trial of 2900 patients assessing the ...

Addressing dyslipidemia is crucial to reducing the burden imposed by cardiovascular disease. However, many current statins have major limitations. Moreover, innovative treatments need to address ...